Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Monteleone

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|November 21, 2015
Stochastic nonlinear mixed effects: a metformin case studyBrett Matzuka, Jason Chittenden, Jonathan Monteleone, et al.
Clinical Pharmacology in Drug Development|April 9, 2024
A Population Pharmacokinetic Assessment of the Effect of Food on Selumetinib in Patients with Neurofibromatosis Type 1-Related Plexiform Neurofibromas and Healthy VolunteersPeiying Zuo, Million Arefayene, Wei-Jian Pan, et al.
Journal of Clinical Pharmacology|March 12, 2014
Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosisChihiro Hasegawa, Helen Kastrissios, Jonathan Monteleone, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Pharmacokinetics and Pharmacodynamics|November 21, 2015
Stochastic nonlinear mixed effects: a metformin case studyBrett Matzuka, Jason Chittenden, Jonathan Monteleone, et al.
Clinical Pharmacology in Drug Development|April 9, 2024
A Population Pharmacokinetic Assessment of the Effect of Food on Selumetinib in Patients with Neurofibromatosis Type 1-Related Plexiform Neurofibromas and Healthy VolunteersPeiying Zuo, Million Arefayene, Wei-Jian Pan, et al.
Journal of Clinical Pharmacology|March 12, 2014
Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosisChihiro Hasegawa, Helen Kastrissios, Jonathan Monteleone, et al.
Pageof 1